PMID- 17760568
OWN - NLM
STAT- MEDLINE
DCOM- 20071127
LR  - 20151119
IS  - 1041-2972 (Print)
IS  - 1041-2972 (Linking)
VI  - 19
IP  - 9
DP  - 2007 Sep
TI  - Immunoglobulin E-mediated airway inflammation is active in most patients with 
      asthma.
PG  - 439-49
AB  - PURPOSE: To review the role of immunoglobulin E (IgE)-mediated inflammation in 
      the pathogenesis of asthma, limitations of standard therapies, and IgE as a 
      logical target for therapy with omalizumab aimed at attaining asthma symptom 
      control. DATA SOURCES: Review of worldwide scientific literature on the role of 
      IgE-mediated inflammation in patients with asthma, supplemented with a clinical 
      case study. CONCLUSIONS: Clinical trials point to an important role for IgE 
      blocker therapy as an add-on to current therapy to reduce exacerbations and 
      corticosteroid use and to improve quality of life in patients with 
      moderate-to-severe asthma. Omalizumab, a monoclonal antibody that binds IgE, has 
      been shown to be an effective, well-tolerated treatment in these patients. 
      IMPLICATIONS FOR PRACTICE: A significant number of patients with 
      moderate-to-severe asthma do not achieve asthma symptom control, despite adhering 
      to current guidelines-based standards of therapy, including the use of inhaled 
      corticosteroids, beta-agonists, and leukotriene modifiers. None of these 
      therapies directly addresses IgE-mediated inflammation. Therefore, patients with 
      persistent symptoms of moderate-to-severe asthma should be evaluated and 
      considered for therapy with the IgE blocker omalizumab.
FAU - Hayden, Mary Lou
AU  - Hayden ML
AD  - School of Nursing, University of Virginia, Richmond, Virginia, USA. 
      mlhayden@vaallergy.com
LA  - eng
PT  - Case Reports
PT  - Journal Article
PT  - Review
PL  - United States
TA  - J Am Acad Nurse Pract
JT  - Journal of the American Academy of Nurse Practitioners
JID - 8916634
RN  - 0 (Adrenergic beta-Agonists)
RN  - 0 (Anti-Asthmatic Agents)
RN  - 0 (Anti-Inflammatory Agents)
RN  - 0 (Antibodies, Anti-Idiotypic)
RN  - 0 (Antibodies, Monoclonal)
RN  - 0 (Antibodies, Monoclonal, Humanized)
RN  - 0 (Leukotriene Antagonists)
RN  - 2P471X1Z11 (Omalizumab)
RN  - 37341-29-0 (Immunoglobulin E)
MH  - Adrenergic beta-Agonists/therapeutic use
MH  - Adult
MH  - Anti-Asthmatic Agents/immunology/therapeutic use
MH  - Anti-Inflammatory Agents/immunology/therapeutic use
MH  - Antibodies, Anti-Idiotypic
MH  - Antibodies, Monoclonal/immunology/therapeutic use
MH  - Antibodies, Monoclonal, Humanized
MH  - *Asthma/drug therapy/etiology/immunology
MH  - Female
MH  - Guideline Adherence
MH  - Humans
MH  - *Hypersensitivity, Immediate/complications/drug therapy/immunology
MH  - Immunoglobulin E/drug effects/immunology
MH  - Inflammation
MH  - Leukotriene Antagonists/therapeutic use
MH  - Mast Cells/immunology
MH  - Nurse Practitioners
MH  - Omalizumab
MH  - Patient Selection
MH  - Practice Guidelines as Topic
MH  - Primary Health Care/*methods
MH  - Risk Factors
MH  - Severity of Illness Index
RF  - 74
EDAT- 2007/09/01 09:00
MHDA- 2007/12/06 09:00
CRDT- 2007/09/01 09:00
PHST- 2007/09/01 09:00 [pubmed]
PHST- 2007/12/06 09:00 [medline]
PHST- 2007/09/01 09:00 [entrez]
AID - JAAN251 [pii]
AID - 10.1111/j.1745-7599.2007.00251.x [doi]
PST - ppublish
SO  - J Am Acad Nurse Pract. 2007 Sep;19(9):439-49. doi: 
      10.1111/j.1745-7599.2007.00251.x.